Newsfeeds Archive - Page 46 of 194

1 minute read

M&A
News

Dr. Reddy’s Laboratories Announced Late Sunday Agreement To Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

February 27, 6:27 AM

Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX).

RDY

1 minute read

Molekule Group Announced Late Sunday It Had Entered Into A Definitive Agreement To Acquire Aura Smart Air Ltd. In An All-Stock Deal Worth ~$10M

By Charles Gross

February 27, 6:11 AM

Molekule Group, Inc. ("Molekule" or the "Company") (NASDAQ: MKUL) announced it has entered into a definitive agreement to acquire Aura Smart Air Ltd. ("Aura"), an Israeli-based company currently listed on the Tel Aviv Stock Exchange, in an all-stock merger with a value of approximately $10 million (the "Merger").

MKUL

1 minute read

Soroban Capital Partners Pushes for Ouster of Union Pacific CEO; Proposes Former Union Pacific Executive Jim Vena for Top Job

By Charles Gross

February 26, 1:01 PM

-Wall Street Journal

UNP

1 minute read

Bloomberg’s Mark Gurman Reported Apple’s Upcoming Headset Likely Won’t Need An iPhone

By Charles Gross

February 26, 12:49 PM

https://www.bloomberg.com/news/newsletters/2023-02-26/apple-aapl-exploratory-design-group-xdg-no-prick-glucose-tracker#:~:text=The%20Apple%20headset%20probably%20won,iPhone%20for%20setup%20or%20use.

AAPL

1 minute read

Apple To Implement Scheduling Changes For All U.S. And Canada Retail Employees

By Charles Gross

February 26, 11:15 AM

-Bloomberg https://www.bloomberg.com/news/newsletters/2023-02-26/apple-aapl-exploratory-design-group-xdg-no-prick-glucose-tracker

AAPL

1 minute read

Events
News

Celldex Therapeutics Presented Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023; Said Rapid, Profound And Durable Responses Across Multiple Dosing Groups With Favorable Safety Profile Observed

By Charles Gross

February 26, 10:26 AM

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today updated data from the Company's Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.

CLDX

1 minute read

Nokia Announced New Brand Identity; Plans To Review Business Units For Alternatives, Including Possible Divestment; CEO Lundmark Said Seeks to Increase Enterprise Business From 8% of Sales To Double-Digits

By Charles Gross

February 26, 10:17 AM

-Reuters https://www.reuters.com/technology/nokia-changes-iconic-logo-signal-strategy-shift-2023-02-26/

NOK

1 minute read

News
Tech

Apple Analyst Ming-Chi Kuo Tweeted: The Prediction For The Mass Shipment Schedule Is Unchanged, But The Likelihood Of Apple’s 1st-gen AR/MR Headset Release At The Spring Event Is Decreasing. Meanwhile, The Probability Of The Headset Launch Alongside Ip…

By Charles Gross

February 24, 7:55 AM

https://twitter.com/mingchikuo/status/1629084937013067777?s=20

AAPL

1 minute read

News
Tech

Tesla Tweeted: Our Global HQ Remains In Austin. Our New Engineering HQ In Palo Alto Will Serve As The Main Location For Tesla Engineering.

By Charles Gross

February 23, 8:00 PM

https://twitter.com/Tesla/status/1628905429152550913?s=20

TSLA

1 minute read

FDA
News

Earlier, Sanofi Announced FDA Approved Once-Weekly Altuviiio, New Class of Factor VIII Therapy For Hemophilia A That Offers Significant Bleed Protection

By Charles Gross

February 23, 7:50 PM

The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy.The U.S.

SNY